Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.50 |
| ▸ | CTSS | P25774 | 8/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17537321 | 1.00 | CTSK (0.50) | CTSKCTSSCA1CA2HDAC4 | |
| SCHEMBL17537319 | 0.91 | CTSK (0.51) | CTSKCTSSCA1CA2HDAC4 | |
| SCHEMBL17133625 | 0.91 | CTSK (0.51) | CTSKCTSSCA1CA2HDAC4 | |
| SCHEMBL17133630 | 0.89 | CTSK (0.59) | CTSKCTSSCA1CA2HDAC4 | |
| SCHEMBL17133715 | 0.89 | CTSK (0.60) | CTSKCTSSCA1CA2HDAC4 | |
| SCHEMBL15083612 | 0.88 | CTSK (0.63) | CTSKCTSSCA1CA2HDAC4 | |
| SCHEMBL17133720 | 0.88 | CTSK (0.63) | CTSKCTSSCA1CA2HDAC4 | |
| SCHEMBL17133689 | 0.87 | CA2 (0.56) | CTSKCTSSCA1CA2CTSB | |
| SCHEMBL17537317 | 0.87 | CA2 (0.56) | CTSKCTSSCA1CA2CTSB | |
| SCHEMBL17133685 | 0.87 | CTSK (0.48) | CTSKCTSSCA1CA2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388123-B2 | LSD1-selective inhibitor having lysine structure | KYOTO UNIVERSITY (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KYOTO UNIVERSITY (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2927212-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | Kyoto University (JP) | 2015-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039748-A1 | LSD1-SELECTIVE INHIBITOR HAVING LYSINE STRUCTURE | KDM1A, DOT1L, KDM1B | CTSK 2479/4885CTSS 2069/4885CA1 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.